WallStSmart
PHAT

Phathom Pharmaceuticals Inc

NASDAQ: PHAT · HEALTHCARE · BIOTECHNOLOGY

$11.78
+3.97% today

Updated 2026-04-29

Market cap
$935.69M
P/E ratio
P/S ratio
5.34x
EPS (TTM)
$-3.03
Dividend yield
52W range
$2 – $18
Volume
1.2M

Phathom Pharmaceuticals Inc (PHAT) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+40.5%
Last 4 quarters
Revenue YoY growth
+94.1%
Most recent quarter
EPS YoY growth
+92.4%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+3.0%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+12.2%
2025-08-07
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-03$-0.08+81.0%$11.46$11.06-3.5%
2025-10-30$-0.15+68.1%$13.53$13.55+0.1%
2025-08-07$-0.79+13.2%$8.68$9.74+12.2%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.42$-0.08+81.0%$57.58M+94.1%
2025-09-30$-0.47$-0.15+68.1%$49.50M+202.7%
2025-06-30$-0.91$-0.79+13.2%$39.50M+439.4%
2025-03-31$-1.07$-1.07-0.4%$28.52M+1391.6%
2024-12-31$-1.08$-1.05+2.8%$29.66M+4249.6%
2024-09-30$-1.49$-1.32+11.4%$16.35M
2024-06-30$-1.38$-1.56-13.0%$7.32M
2024-03-31$-1.31$-1.42-8.4%$1.91M
2023-12-31$-1.08$-1.39-28.7%$682000.00
2023-09-30$-0.89$-0.76+14.6%
2023-06-30$-0.98$-0.84+14.3%

Frequently asked questions

Has Phathom Pharmaceuticals Inc beaten earnings estimates?
Phathom Pharmaceuticals Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +40.5% over the last 4 quarters.
How does PHAT stock react to earnings?
PHAT stock has moved an average of +3.0% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Phathom Pharmaceuticals Inc's revenue growth rate?
Phathom Pharmaceuticals Inc reported year-over-year revenue growth of +94.1% in its most recent quarter, with EPS growing +92.4% year-over-year.